Determining individual trajectories of joint space loss: improved statistical methods for monitoring knee osteoarthritis disease progression.


Journal

Osteoarthritis and cartilage
ISSN: 1522-9653
Titre abrégé: Osteoarthritis Cartilage
Pays: England
ID NLM: 9305697

Informations de publication

Date de publication:
01 2021
Historique:
received: 18 03 2020
revised: 21 07 2020
accepted: 02 09 2020
pubmed: 28 11 2020
medline: 15 12 2021
entrez: 27 11 2020
Statut: ppublish

Résumé

Knee osteoarthritis (KOA) progression is frequently monitored by calculating the change in knee joint space width (JSW) measurements. Such differences are small and sensitive to measurement error. We aimed to assess the utility of two alternative statistical modelling methods for monitoring KOA. We used JSW on radiographs from both the control arm of the Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA), a 3-year multicentre, double-blind, placebo-controlled phase three trial, and the Osteoarthritis Initiative (OAI), an open-access longitudinal dataset from the USA comprising participants followed over 8 years. Individual estimates of annualised change obtained from frequentist linear mixed effect (LME) and Bayesian hierarchical modelling, were compared with annualised crude change, and the association of these parameters with change in WOMAC pain was examined. Mean annualised JSW changes were comparable for all estimates, a reduction of around 0.14 mm/y in SEKOIA and 0.08 mm/y in OAI. The standard deviation (SD) of change estimates was lower with LME and Bayesian modelling than crude change (SEKOIA SD = 0.12, 0.12 and 0.21 respectively; OAI SD = 0.08, 0.08 and 0.11 respectively). Estimates from LME and Bayesian modelling were statistically significant predictors of change in pain in SEKOIA (LME P-value = 0.04, Bayes P-value = 0.04), while crude change did not predict change in pain (P-value = 0.10). Implementation of LME or Bayesian modelling in clinical trials and epidemiological studies, would reduce sample sizes by enabling all study participants to be included in analysis regardless of incomplete follow up, and precision of change estimates would improve. They provide increased power to detect associations with other measures.

Identifiants

pubmed: 33246159
pii: S1063-4584(20)31179-1
doi: 10.1016/j.joca.2020.09.009
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-67

Subventions

Organisme : Medical Research Council
ID : MC_UP_A620_1015
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585827
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585819
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A620_1014
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400491
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585824
Pays : United Kingdom
Organisme : Department of Health
ID : 10/33/04
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Auteurs

C M Parsons (CM)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK. Electronic address: cp@mrc.soton.ac.uk.

A Judge (A)

Musculoskeletal Research Unit, University of Bristol, Bristol, UK. Electronic address: Andrew.judge@bristol.ac.uk.

R Meyer (R)

Department of Statistics, University of Auckland, New Zealand. Electronic address: renate.meyer@auckland.ac.nz.

O Bruyère (O)

Department of Public Health and Health Economics, University of Liege, 4020, Liege, Belgium. Electronic address: olivier.bruyere@uliege.be.

F Petit-Dop (F)

Innovative Therapeutic Pole of Rheumatology, Servier, Surenes, France. Electronic address: Florence.petit-dop@servier.com.

R Chapurlat (R)

INSERUM UMR 1033, Service de Rhumatolgie et Pathologie Osseuse, Hopital Edouard Herriot, Universite de Lyon, Lyon, France. Electronic address: roland.chapurlat@inserm.fr.

J-Y Reginster (JY)

Department of Public Health and Health Economics, University of Liege, 4020, Liege, Belgium. Electronic address: jyreginster@ulg.ac.be.

C Cooper (C)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK; National Institute for Health Research Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK; National Institute for Health Research Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, UK. Electronic address: cc@mrc.soton.ac.uk.

H Inskip (H)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK. Electronic address: hmi@mrc.soton.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH